Masahiro Sugihara

3.8k total citations · 4 hit papers
54 papers, 2.6k citations indexed

About

Masahiro Sugihara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Masahiro Sugihara has authored 54 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in Masahiro Sugihara's work include HER2/EGFR in Cancer Research (24 papers), Gastric Cancer Management and Outcomes (13 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Masahiro Sugihara is often cited by papers focused on HER2/EGFR in Cancer Research (24 papers), Gastric Cancer Management and Outcomes (13 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Masahiro Sugihara collaborates with scholars based in Japan, United States and South Korea. Masahiro Sugihara's co-authors include Kaku Saito, Hiroji Iwata, Junji Tsurutani, Shunji Takahashi, Toshihiko Doi, Kenji Tamura, Haeseong Park, Kohei Shitara, Kensei Yamaguchi and Satoru Iwasa and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Masahiro Sugihara

47 papers receiving 2.6k citations

Hit Papers

Trastuzumab Deruxtecan in... 2019 2026 2021 2023 2020 2020 2019 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    2020 802 citations Kohei Shitara, Yung‐Jue Bang et al. New England Journal of Medicine profile →
  2. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
    2020 551 citations Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology profile →
  3. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
    2019 258 citations Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology profile →
  4. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
    2020 248 citations Junji Tsurutani, Hiroji Iwata et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Masahiro Sugihara Japan 16 2.0k 1.2k 905 356 355 54 2.6k
Yasutoshi Kuboki Japan 27 2.1k 1.0× 1.2k 1.0× 331 0.4× 556 1.6× 309 0.9× 143 2.8k
Andreas H. Marx Germany 26 1.3k 0.6× 822 0.7× 259 0.3× 698 2.0× 301 0.8× 75 2.2k
Giancarlo Bisagni Italy 25 1.9k 1.0× 832 0.7× 918 1.0× 570 1.6× 747 2.1× 127 2.9k
Hisato Kawakami Japan 32 2.7k 1.3× 1.6k 1.4× 662 0.7× 834 2.3× 508 1.4× 179 3.8k
S. Tjulandin Russia 20 1.4k 0.7× 596 0.5× 357 0.4× 277 0.8× 724 2.0× 75 2.1k
Vichien Srimuninnimit Thailand 21 2.9k 1.4× 1.6k 1.3× 794 0.9× 530 1.5× 1.7k 4.7× 67 3.8k
Akihiko Shimomura Japan 22 1.1k 0.5× 536 0.5× 331 0.4× 751 2.1× 537 1.5× 132 2.0k
Jayantha Ratnayake United Kingdom 10 2.2k 1.1× 574 0.5× 849 0.9× 363 1.0× 1.4k 3.9× 14 2.8k
R. Mass United States 21 2.5k 1.2× 1.2k 1.0× 594 0.7× 1.0k 2.9× 503 1.4× 43 3.4k
Tanja Trarbach Germany 25 1.7k 0.9× 1.2k 1.0× 158 0.2× 775 2.2× 351 1.0× 93 2.6k

Countries citing papers authored by Masahiro Sugihara

Since Specialization
Citations

This map shows the geographic impact of Masahiro Sugihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masahiro Sugihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masahiro Sugihara more than expected).

Fields of papers citing papers by Masahiro Sugihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masahiro Sugihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masahiro Sugihara. The network helps show where Masahiro Sugihara may publish in the future.

Co-authorship network of co-authors of Masahiro Sugihara

This figure shows the co-authorship network connecting the top 25 collaborators of Masahiro Sugihara. A scholar is included among the top collaborators of Masahiro Sugihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masahiro Sugihara. Masahiro Sugihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takahashi, Shunji, Hideaki Bando, Ichiro Kinoshita, et al.. (2024). Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese Journal of Clinical Oncology. 54(4). 434–443. 6 indexed citations
2.
3.
Shitara, Kohei, Kensei Yamaguchi, Kei Muro, et al.. (2023). Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study. International Journal of Clinical Oncology. 29(1). 27–35. 2 indexed citations
4.
5.
Yasui, Hisateru, Atsushi Takeno, Hiroki Hara, et al.. (2022). Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study. International Journal of Colorectal Disease. 37(6). 1393–1402. 8 indexed citations
6.
Tsurutani, Junji, Hiroji Iwata, Ian E. Krop, et al.. (2020). Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery. 10(5). 688–701. 248 indexed citations breakdown →
7.
Shitara, Kohei, Yung‐Jue Bang, Satoru Iwasa, et al.. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine. 382(25). 2419–2430. 802 indexed citations breakdown →
8.
Saito, Kaku, et al.. (2020). Pharmacological and clinical study results of trastuzumab deruxtecan (T-DXd, ENHERTU<sup>®</sup>). Folia Pharmacologica Japonica. 156(1). 47–51. 2 indexed citations
9.
10.
Tamura, Kenji, Junji Tsurutani, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 816–826. 258 indexed citations breakdown →
11.
Shitara, Kohei, Hiroji Iwata, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 827–836. 162 indexed citations
12.
Lee, Jih‐Hsiang, Tom Wei‐Wu Chen, Chih‐Hung Hsu, et al.. (2019). A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Investigational New Drugs. 38(1). 99–110. 52 indexed citations
13.
Nakamura, Mitsugu, et al.. (2017). Impact of Additional Lipid-Lowering Therapy on New Ischemic Lesions of Diffusion-Weighted Imaging in Carotid Artery Stenting. Journal of Stroke and Cerebrovascular Diseases. 27(3). 764–770. 6 indexed citations
14.
Takano, Masashi, Kaichiro Yamamoto, Tsutomu Tabata, et al.. (2016). Impact ofUGT1A1genotype upon toxicities of combination with low-dose irinotecan plus platinum. Asia-Pacific Journal of Clinical Oncology. 12(2). 115–124. 11 indexed citations
15.
Sadamori, Hiroshi, Takahito Yagi, Kunitoshi Shigeyasu, et al.. (2013). Advanced hepatocellular carcinoma with lymph node metastases showing epithelial to mesenchymal transition effectively treated with systemic chemotherapy: Report of a case. Hepatology Research. 43(12). 1368–1373. 4 indexed citations
16.
Sugihara, Masahiro, Hiroyoshi Matsukawa, Yasuhiro Fujiwara, et al.. (2011). ACUTE SUPERIOR MESENTERIC VEIN THROMBOSIS ASSOCIATED WITH CONGENITAL ANTITHROMBIN-III DEFICIENCY-A CASE REPORT-. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 72(2). 494–499.
17.
Sugihara, Masahiro, Masahiko Nishizaki, Hiroyoshi Matsukawa, et al.. (2011). GIANT CYST-CONTAINING GASTROINTESTINAL STROMAL TUMOR OF THE STOMACH, WHICH DEVELOPED OUTSIDE THE GASTRIC WALL-A CASE REPORT-. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 72(7). 1739–1743.
18.
Nakamura, Mitsugu, et al.. (2011). Significance of blood aspiration in carotid artery stenting with Angioguard XP. Journal of Vascular Surgery. 53(6). 1478–1484. 4 indexed citations
19.
Sugihara, Masahiro. (2009). Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score. Pharmaceutical Statistics. 9(1). 21–34. 41 indexed citations
20.
Matsushita, Yasuyuki, et al.. (2009). Pravastatin use and cancer risk: a meta‐analysis of individual patient data from long‐term prospective controlled trials in Japan. Pharmacoepidemiology and Drug Safety. 19(2). 196–202. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasutoshi Kuboki Breakdown of academic impact, for papers by Andreas H. Marx Breakdown of academic impact, for papers by Giancarlo Bisagni Breakdown of academic impact, for papers by Hisato Kawakami Breakdown of academic impact, for papers by S. Tjulandin Breakdown of academic impact, for papers by Vichien Srimuninnimit Breakdown of academic impact, for papers by Akihiko Shimomura Breakdown of academic impact, for papers by Jayantha Ratnayake Breakdown of academic impact, for papers by R. Mass Breakdown of academic impact, for papers by Tanja Trarbach
Rankless by CCL
2026